These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

449 related articles for article (PubMed ID: 26607030)

  • 1. Impact of Variations in Kidney Function on Nonvitamin K Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Recent Acute Heart Failure.
    Andreu-Cayuelas JM; Pastor-Pérez FJ; Puche CM; Mateo-Martínez A; García-Alberola A; Flores-Blanco PJ; Valdés M; Lip GY; Roldán V; Manzano-Fernández S
    Rev Esp Cardiol (Engl Ed); 2016 Feb; 69(2):134-40. PubMed ID: 26607030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of estimated glomerular filtration rate equations for dosing new oral anticoagulants in patients with atrial fibrillation.
    Manzano-Fernández S; Andreu-Cayuelas JM; Marín F; Orenes-Piñero E; Gallego P; Valdés M; Vicente V; Lip GY; Roldán V
    Rev Esp Cardiol (Engl Ed); 2015 Jun; 68(6):497-504. PubMed ID: 25457087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kidney function monitoring and nonvitamin K oral anticoagulant dosage in atrial fibrillation.
    Andreu Cayuelas JM; Caro Martínez C; Flores Blanco PJ; Elvira Ruiz G; Albendin Iglesias H; Cerezo Manchado JJ; Bailen Lorenzo JL; Januzzi JL; García Alberola A; Manzano-Fernández S
    Eur J Clin Invest; 2018 Jun; 48(6):e12907. PubMed ID: 29423910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apixaban, Rivaroxaban, and Dabigatran in Patients Undergoing Atrial Fibrillation Ablation.
    Rillig A; Lin T; Plesman J; Heeger CH; Lemes C; Metzner A; Mathew S; Wissner E; Wohlmuth P; Ouyang F; Kuck KH; Tilz RR
    J Cardiovasc Electrophysiol; 2016 Feb; 27(2):147-53. PubMed ID: 26464027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
    Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Hylek E; Kowey PR; Mahaffey KW; O'Brien EC; Singer DE; Peterson ED; Piccini JP;
    Am Heart J; 2017 Jul; 189():40-47. PubMed ID: 28625380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy.
    Barra ME; Fanikos J; Connors JM; Sylvester KW; Piazza G; Goldhaber SZ
    Am J Med; 2016 Nov; 129(11):1198-1204. PubMed ID: 27341955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction.
    Yao X; Shah ND; Sangaralingham LR; Gersh BJ; Noseworthy PA
    J Am Coll Cardiol; 2017 Jun; 69(23):2779-2790. PubMed ID: 28595692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non-vitamin K antagonist oral anticoagulant dose adjustment.
    Hawkins NM; Jhund PS; Pozzi A; O'Meara E; Solomon SD; Granger CB; Yusuf S; Pfeffer MA; Swedberg K; Petrie MC; Virani S; McMurray JJ
    Eur J Heart Fail; 2016 Sep; 18(9):1162-71. PubMed ID: 27594177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration.
    Borne RT; O'Donnell C; Turakhia MP; Varosy PD; Jackevicius CA; Marzec LN; Masoudi FA; Hess PL; Maddox TM; Ho PM
    BMC Cardiovasc Disord; 2017 Sep; 17(1):236. PubMed ID: 28865440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world adherence for direct oral anticoagulants in a newly diagnosed atrial fibrillation cohort: does the dosing interval matter?
    Pham PN; Brown JD
    BMC Cardiovasc Disord; 2019 Mar; 19(1):64. PubMed ID: 30890131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Left atrial thrombus and dense spontaneous echocardiographic contrast in patients on continuous direct oral anticoagulant therapy undergoing catheter ablation of atrial fibrillation: Comparison of dabigatran, rivaroxaban, and apixaban.
    Wu M; Gabriels J; Khan M; Shaban N; D'Amato S; Liu CF; Markowitz SM; Ip JE; Thomas G; Singh P; Lerman B; Patel A; Cheung JW
    Heart Rhythm; 2018 Apr; 15(4):496-502. PubMed ID: 29605015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prescribing of Direct Oral Anticoagulants in Atrial Fibrillation Based on Estimation of Renal Function Using Standard and Modified Cockcroft-Gault Equations: A Retrospective Analysis.
    Kucey M; Bolt J; Albers L; Bell A; Iroh N; Toppings J
    Can J Hosp Pharm; 2016; 69(5):409-414. PubMed ID: 27826159
    [No Abstract]   [Full Text] [Related]  

  • 13. Appropriateness of initial dose of non-vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation in the UK.
    García Rodríguez LA; Martín-Pérez M; Vora P; Roberts L; Balabanova Y; Brobert G; Fatoba S; Suzart-Woischnik K; Schaefer B; Ruigomez A
    BMJ Open; 2019 Sep; 9(9):e031341. PubMed ID: 31542760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic review of cost-effectiveness analyses of novel oral anticoagulants for stroke prevention in atrial fibrillation.
    Ferreira J; Mirco A
    Rev Port Cardiol; 2015 Mar; 34(3):179-91. PubMed ID: 25727748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends in oral anticoagulant choice for acute stroke patients with nonvalvular atrial fibrillation in Japan: the SAMURAI-NVAF study.
    Toyoda K; Arihiro S; Todo K; Yamagami H; Kimura K; Furui E; Terasaki T; Shiokawa Y; Kamiyama K; Takizawa S; Okuda S; Okada Y; Kameda T; Nagakane Y; Hasegawa Y; Mochizuki H; Ito Y; Nakashima T; Takamatsu K; Nishiyama K; Kario K; Sato S; Koga M;
    Int J Stroke; 2015 Aug; 10(6):836-42. PubMed ID: 25581108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparison of the cost-utility of direct oral anticoagulants for the prevention of stroke in patients with atrial fibrillation in Spain].
    Monreal-Bosch M; Soulard S; Crespo C; Brand S; Kansal A
    Rev Neurol; 2017 Mar; 64(6):247-256. PubMed ID: 28272725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups.
    Lip GY; Mitchell SA; Liu X; Liu LZ; Phatak H; Kachroo S; Batson S
    Int J Cardiol; 2016 Feb; 204():88-94. PubMed ID: 26655548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initiation and continuation of oral anticoagulant prescriptions for stroke prevention in non-valvular atrial fibrillation: A cohort study in primary care in France.
    Collings SL; Vannier-Moreau V; Johnson ME; Stynes G; Lefèvre C; Maguire A; Asmar J; Bizouard G; Duhot D; Mouquet F; Fauchier L
    Arch Cardiovasc Dis; 2018 May; 111(5):370-379. PubMed ID: 29398546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the Incidences of Complications After Second-Generation Cryoballoon Ablation of Atrial Fibrillation Using Vitamin K Antagonists Versus Novel Oral Anticoagulants.
    Mugnai G; de Asmundis C; Iacopino S; Stroker E; Longobardi M; De Regibus V; Coutino-Moreno HE; Takarada K; Choudhury R; Abugattas de Torres JP; Storti C; Brugada P; Chierchia GB
    Am J Cardiol; 2017 Jul; 120(2):223-229. PubMed ID: 28532773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of indications for reduced-dose non-vitamin K antagonist oral anticoagulants in hospitalised patients with atrial fibrillation.
    Jelonek O; Gorczyca I; Bączek M; Kośmider P; Wożakowska-Kapłon B
    Kardiol Pol; 2018; 76(7):1073-1080. PubMed ID: 29441513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.